Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation

It is known that multiple myeloma (MM) cells express CD38 and that a recently developed human anti-CD38 monoclonal antibody Daratumumab mediates myeloma killing. However, the expression of CD38 and other functionally related ectoenzymes within the MM bone niche and the potential effects of Daratumum...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Federica, Toscani, Denise, Chillemi, Antonella, Quarona, Valeria, Bolzoni, Marina, Marchica, Valentina, Vescovini, Rosanna, Mancini, Cristina, Martella, Eugenia, Campanini, Nicoletta, Schifano, Chiara, Bonomini, Sabrina, Accardi, Fabrizio, Horenstein, Alberto L., Aversa, Franco, Malavasi, Fabio, Giuliani, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593586/
https://www.ncbi.nlm.nih.gov/pubmed/28915615
http://dx.doi.org/10.18632/oncotarget.17896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593586/
https://www.ncbi.nlm.nih.gov/pubmed/28915615
http://dx.doi.org/10.18632/oncotarget.17896

Ejemplares similares